Advantage Alpha Capital Partners LP Protagonist Therapeutics, Inc Transaction History
Advantage Alpha Capital Partners LP
- $387 Million
- Q4 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 5,742 shares of PTGX stock, worth $222,502. This represents 0.06% of its overall portfolio holdings.
Number of Shares
5,742
Previous 11,336
49.35%
Holding current value
$222,502
Previous $509,000
56.58%
% of portfolio
0.06%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$230 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$223 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$213 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$164 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.9B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...